Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 8:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 110 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ivacaftor Clear all
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis

NCT03911713
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-561, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
30
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2022 · Synced Sep 2, 2026, 8:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor

NCT01899105
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
lumacaftor, ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Apr 2, 2014 · Synced Sep 2, 2026, 8:35 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Lumacaftor and Ivacaftor Combination Therapy in Subjects 12 Years and Older With Advanced Lung Disease

NCT02390219
View directory record Official record
Conditions
Cystic Fibrosis, Advanced Lung Disease
Interventions
Lumacaftor, Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Denver, Colorado • Tampa, Florida • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Sep 2, 2026, 8:35 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

NCT01931839
View directory record Official record
Conditions
Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Interventions
Lumacaftor Plus Ivacaftor Combination, Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
1,164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
91
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 88 more
Source: ClinicalTrials.gov public record
Updated May 11, 2017 · Synced Sep 2, 2026, 8:35 PM EDT
Completed Phase 2 Interventional Results available

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

NCT01225211
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Lumacaftor, Ivacaftor, Lumacaftor Placebo, Ivacaftor Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
38
States / cities
Birmingham, Alabama • Anchorage, Alaska • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Sep 2, 2026, 8:35 PM EDT
Completed Phase 3 Interventional Results available

Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and Older

NCT04183790
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated May 17, 2025 · Synced Sep 2, 2026, 8:35 PM EDT
Completed Phase 3 Interventional Results available

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

NCT03601637
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LUM, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Months to 23 Months
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Palo Alto, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Sep 2, 2026, 8:35 PM EDT
Completed No phase listed Observational

Ivacaftor Treatment in 4 Month to 2 Year Old CF Subjects

NCT03783286
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
4 Months to 2 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Sep 2, 2026, 8:35 PM EDT
Completed No phase listed Observational

Ivacaftor (Kalydeco) and Insulin in Cystic Fibrosis (CF)

NCT02039986
View directory record Official record
Conditions
Cystic Fibrosis Related Diabetes, Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Sep 2, 2026, 8:35 PM EDT
Active, not recruiting No phase listed Observational

Ivacaftor Impact in an Adolescent Without a Cystic Fibrosis-Associated CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) Mutation for Chronic Pancreatitis: Single-Patient Study Tracking Flare Frequency and Health Data Compared to Historical Records.

NCT07022327
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Ivacaftor 150 MG (milligrams)
Drug
Lead sponsor
Mission: Cure
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 14, 2025 · Synced Sep 2, 2026, 8:35 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis

NCT02951182
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
TEZ, IVA, VX-440, Matched Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
22
States / cities
Tucson, Arizona • Palo Alto, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2020 · Synced Sep 2, 2026, 8:35 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Cystic Fibrosis Related Bone Disease: the Role of CFTR

NCT01549314
View directory record Official record
Conditions
Cystic Fibrosis Related Bone Disease
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
6 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Sep 2, 2026, 8:35 PM EDT
Completed Phase 2 Interventional Results available

Study of the Effect of Ivacaftor on Lung Clearance Index in Subjects With Cystic Fibrosis and the G551D Mutation

NCT01262352
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
4
States / cities
Stanford, California • Iowa City, Iowa • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2013 · Synced Sep 2, 2026, 8:35 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Ivacaftor in Patients Using Ataluren for Nonsense Mutations

NCT03256799
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor/Ataluren
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 18, 2019 · Synced Sep 2, 2026, 8:35 PM EDT
Completed Phase 3 Interventional Results available

Study of Ivacaftor in Cystic Fibrosis Subjects 2 Through 5 Years of Age With a CFTR Gating Mutation

NCT01705145
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Ivacaftor
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
2 Years to 5 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
16
States / cities
Birmingham, Alabama • Aurora, Colorado • Atlanta, Georgia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2016 · Synced Sep 2, 2026, 8:35 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety, Tolerability, PK and PD of ELX-02 in Cystic Fibrosis Patients With G542X Allele

NCT04135495
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX-02, Ivacaftor
Drug
Lead sponsor
Eloxx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
7
States / cities
Long Beach, California • Palo Alto, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2022 · Synced Sep 2, 2026, 8:35 PM EDT
Completed Phase 3 Interventional Results available

A Study of VX-445 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

NCT03525548
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-445/TEZ/IVA, TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
28
States / cities
Tucson, Arizona • Little Rock, Arkansas • Long Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 2, 2026, 8:35 PM EDT
Completed No phase listed Observational

A Decentralized Study to Evaluate Physical Activity and Cough Frequency Using Wearable Technology in Cystic Fibrosis

NCT04923464
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Not listed
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
11
States / cities
Denver, Colorado • New Haven, Connecticut • Orlando, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Sep 2, 2026, 8:35 PM EDT
Recruiting No phase listed Observational

Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)

NCT06683092
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
RETRIAL-Mental Health, RETRIAL-Liver, RETRIAL-Neuro
Other
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Aurora, Colorado • Denver, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Sep 2, 2026, 8:35 PM EDT
Completed Phase 3 Interventional Results available

A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del Mutation

NCT05076149
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-121/TEZ/D-IVA, ELX/TEZ/IVA, IVA, Placebo (matched to VX-121/TEZ/D-IVA), Placebo (matched to ELX/TEZ/IVA), Placebo (matched to IVA)
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
62
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Sep 2, 2026, 8:35 PM EDT
Completed Phase 2 Interventional

Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation

NCT02589236
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Cavosonstat, Placebo
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
46
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 42 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 2, 2026, 8:35 PM EDT
Completed Phase 3 Interventional Results available

A Study of VX-659 Combination Therapy in CF Subjects Homozygous for F508del (F/F)

NCT03460990
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
VX-659/TEZ/IVA, TEZ/IVA, IVA, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
28
States / cities
Birmingham, Alabama • New Haven, Connecticut • Miami, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Sep 2, 2026, 8:35 PM EDT
Completed Phase 2 Interventional Results available

Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia

NCT02871778
View directory record Official record
Conditions
Primary Ciliary Dyskinesia
Interventions
VX-371, Hypertonic Saline, Placebo (0.17% saline), VX-371 + HS, Ivacaftor
Drug
Lead sponsor
Parion Sciences
Industry
Eligibility
12 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
21
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Sep 2, 2026, 8:35 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661/Ivacaftor in Pediatric Subjects With Cystic Fibrosis (CF)

NCT02953314
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
TEZ, TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
30
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Sep 2, 2026, 8:35 PM EDT